Pandemic-era disruptions left a visible imprint on screening-detected cancers
Population-based cancer registries are built to reveal slow-moving change, and this SEER study does exactly that. Using U.S. registry data from 2000 through 2022, investigators examined age-adjusted incidence trends for lung and bronchus, colon and rectum, breast, and cervix uteri cancers among adults aged 40 years and older. The central story is not uniform decline across all screened cancers. Instead, three sites moved downward over time, breast cancer remained comparatively flat, and the COVID-19 era interrupted the expected trajectory for several diagnoses.
Long-term incidence declined significantly for lung and bronchus cancer, colorectal cancer, and cervical cancer. The average annual per cent change was −1.81% for lung and bronchus, −1.94% for colorectal cancer, and −1.48% for cervical cancer across the full study period. Breast cancer stood apart, with no significant overall change; its average annual per cent change was −0.32%. Those differences fit the biology and the public health context. Lung cancer incidence has been pulled down for years by lower smoking prevalence and downstream reductions in tobacco-related disease, while colorectal and cervical cancer trends reflect the cumulative effect of screening, lesion removal, and earlier detection before invasive disease develops.
Breast cancer behaved differently because its incidence is shaped by a more complex mix of screening intensity, reproductive factors, hormone exposure, and changing diagnostic thresholds. A stable overall trend does not mean breast cancer screening is unimportant. It means the forces pushing incidence up and down may have roughly balanced each other across the years examined.
The steepest pandemic-era drop came in 2020
The sharpest signal appeared during 2020, when observed incidence rates for several cancers fell below the values expected from pre-pandemic trends. In plain terms, fewer cancers were being found than the underlying secular trend would have predicted. The most pronounced reductions were generally seen in the first pandemic year, with more variable patterns afterward through 2022.
That pattern is clinically credible. Screening colonoscopy, mammography, Pap testing, and follow-up diagnostics all depend on access, staffing, patient willingness, and system capacity. When those channels narrow, incidence curves can fall even if the true underlying burden in the population has not changed. A delayed diagnosis does not erase disease; it moves discovery to a later date, often at a more advanced stage or after symptoms emerge.
The study’s stage distribution findings were more restrained than the incidence shifts. Among diagnosed cases, stage distribution showed only modest year-to-year variation across the four cancer sites. That may reflect the fact that registry-based stage data can be blunt when measured at population scale, or that short-term screening disruptions had not yet fully translated into large stage shifts by 2022. Either way, the absence of dramatic stage redistribution should not be mistaken for reassurance. Cancers missed in 2020 can reappear later, and registry curves often lag behind service disruptions.
Age, sex, race, and stage patterns were not uniform
Descriptive subgroup analyses showed heterogeneous patterns across age, sex, race and ethnicity, and stage. This is exactly where population data become most clinically useful. Cancer screening does not operate on a level field. Access to preventive care, prior utilization of screening, insurance status, geography, and trust in the health system all shape who gets diagnosed and when.
The study did not reduce those subgroup differences to a single simple explanation, and it should not have. Heterogeneity is the epidemiologic fingerprint of unequal access and unequal exposure to preventive care. In some groups, a decline in incidence may reflect truly lower disease burden. In others, it may reflect underdiagnosis, delayed follow-up, or interrupted care pathways. The same incidence curve can therefore represent very different clinical realities depending on the population behind it.
Screening systems, not just biology, determine the curve
The value of this analysis lies in its long time horizon. By contrasting observed pandemic-era incidence with rates projected from pre-2020 trends, the study separates chronic secular change from abrupt service disruption. The results make one point with unusual clarity: screening-sensitive cancers are not measured only by tumor biology. They are also measured by the reliability of the health system that finds them.
For lung, colorectal, and cervical cancer, long-term declines suggest that screening and prevention have mattered at the population level, even if the gains have not been evenly distributed. For breast cancer, a relatively stable trajectory indicates that incidence is being shaped by multiple competing influences rather than by a single dominant preventive force. For the pandemic period, the deviation from expected rates shows how quickly routine cancer detection can be destabilized when health services are interrupted.
This has direct implications for future public health emergencies. Screening programs cannot be treated as optional infrastructure. If preventive services stall, incidence data will change immediately, while downstream mortality and advanced-stage presentations may emerge later. Maintaining access to diagnostic follow-up, preserving outreach to high-risk groups, and restoring routine screening capacity quickly are not abstract policy goals. They are the difference between a temporary data dip and a lasting burden of avoidable late diagnosis.
What this registry signal can and cannot prove
SEER-based analyses are powerful for describing population trends, but they cannot assign causality to a single driver. The study cannot distinguish how much of the incidence decline came from changes in screening uptake, changes in risk factor prevalence, changes in diagnostic coding, or delayed care during the pandemic. It also cannot fully capture the clinical consequences of missed or deferred diagnoses beyond incidence patterns themselves.
Even with those limits, the message is hard to ignore. Population incidence for several screening-linked cancers fell over two decades, then bent away from expectation during the COVID-19 era. Health systems that depend on routine preventive care should view that bend as a warning sign, not a statistical curiosity. Future work will need to connect these incidence disruptions to stage at diagnosis, treatment timing, and survival once the post-pandemic cohort has matured.